Jung, K. H., LoRusso, P., Burris, H., Gordon, M., Bang, Y., Hellmann, M. D., . . . Davis, S. L. (2019). Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clinical cancer research, 25(11), 3220. https://doi.org/10.1158/1078-0432.CCR-18-2740
Chicago-Zitierstil (17. Ausg.)Jung, Kyung Hae, et al. "Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors." Clinical Cancer Research 25, no. 11 (2019): 3220. https://doi.org/10.1158/1078-0432.CCR-18-2740.
MLA-Zitierstil (9. Ausg.)Jung, Kyung Hae, et al. "Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors." Clinical Cancer Research, vol. 25, no. 11, 2019, p. 3220, https://doi.org/10.1158/1078-0432.CCR-18-2740.